/ /

  • linkedin
  • Increase Font
  • Sharebar

    Punctal plug drug delivery attractive method for managing glaucoma


    Present pipeline

    Currently, two companies—Mati Therapeutics and Ocular Therapeutix—are performing clinical trials of punctal plug delivery systems for glaucoma medications.

    The Mati Therapeutics platform (Evolute) has an L-shaped design and is inserted into the nasolacrimal duct. The device is cosmetically invisible, but can be easily seen with eversion of the lower lid.

    The device that was studied for glaucoma has a core of latanoprost-polymer matrix that is surrounded by silicone, and it delivers the medication into the tear film at a constant rate.

    In a phase II clinical trial, the latanoprost punctal plug was found to be comfortable. It was associated with a 20% lowering from baseline IOP over a 3-month period, and in two separate clinical trials, it had a retention rate of 92% and 96%, respectively.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results